Large Liver Mass Found in 53-Year-Old Man

Poll

A 53-year-old man presents with a large hepatic mass. After further evaluation, a biopsy is performed. What is your diagnosis?

A 53-year-old man presents with a large hepatic mass. According to the histopathology image below, what is your diagnosis?

What is your diagnosis?

A. Hepatic adenoma
B. Intrahepatic cholangiocarcinoma
C. Biliary cirrhosis
D. Bile duct adenoma
Recent Videos
3 experts in this video
3 experts in this video
Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.
Data from the SPOTLIGHT and GLOW trials reveal that zolbetuximab increased survival in patients with CLDN18.2-positive gastric or GEJ adenocarcinoma.
The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.
Related Content
Pembrolizumab plus lenvatinib showed a safety profile consistent with previous reports evaluating the combination.

Pembrolizumab Combo Does Not Meet OS End Point in Advanced Gastric Cancer

Roman Fabbricatore
January 27th 2025
Article

Pembrolizumab plus lenvatinib showed a safety profile consistent with previous reports evaluating the combination.

Immunotherapy Treatments Only Just Emerging in Esophageal, Gastric Cancers

Immunotherapy Treatments Only Just Emerging in Esophageal, Gastric Cancers

Geoffrey Y. Ku, MD
January 18th 2017
Podcast

Ahead of the 2017 ASCO Gastrointestinal Cancer Symposium in San Francisco, we spoke with Dr. Geoffrey Ku on the advances in systemic therapy for esophageal and gastric cancer.

Efficacy and Safety of Zolbetuximab in Gastric Cancer

Efficacy and Safety of Zolbetuximab in Gastric Cancer

Aiman Waheed, MBBS;Muhammad Numan Saleem, MBBS;Yash Shah, MD;Muhammad Hamza Gul, MBBS, MD;Helai Hussaini, MD;Abdul Baseer Wardak, MBBS
December 6th 2024
Article

Zolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.

Data from the phase 3 SPOTLIGHT trial and the phase 3 GLOW trial supported the approval of zolbetuximab plus chemotherapy in this indication.

FDA Approves Zolbetuximab in Advanced CLDN18.2+ Gastric/GEJ Adenocarcinoma

Roman Fabbricatore
October 18th 2024
Article

Data from the phase 3 SPOTLIGHT trial and the phase 3 GLOW trial supported the approval of zolbetuximab plus chemotherapy in this indication.

Data from the GLOW and SPOTLIGHT trials support the European Commission’s approval of zolbetuximab for patients with CLDN18.2-positive gastric cancer.

Zolbetuximab Earns European Approval in Advanced CLDN18.2+ Gastric Cancer

Russ Conroy
September 23rd 2024
Article

Data from the GLOW and SPOTLIGHT trials support the European Commission’s approval of zolbetuximab for patients with CLDN18.2-positive gastric cancer.

sNDA of Fruquintinib Combo Withdrawn in China for Second-Line Gastric/GEJ Cancer

sNDA of Fruquintinib Combo Withdrawn in China for Second-Line Gastric/GEJ Cancer

Ariana Pelosci
August 30th 2024
Article

Second-line fruquintinib plus paclitaxel did not sustain sufficient efficacy for patients with advanced gastric or GEJ adenocarcinoma to support approval in China.